Alnylam Pharmaceuticals, Inc Forecast, price target & analysts
Alnylam Pharmaceuticals, Inc Target price 2026 - Analyst rating & recommendation
Alnylam Pharmaceuticals, Inc Classifications & Recommendation
Alnylam Pharmaceuticals, Inc Price Target
| Target Price | $356.49 |
| Price | $232.68 |
| Potential | 53.21% |
| Number of Estimates | 30 |
| 30 Analysts have issued a price target Alnylam Pharmaceuticals, Inc 2027 . The average Alnylam Pharmaceuticals, Inc target price is $356.49. This is 53.21% higher than the current stock price. The highest price target is $594.30 155.42% , the lowest is $238.36 2.44% . | |
| A rating was issued by 38 analysts: 29 Analysts recommend Alnylam Pharmaceuticals, Inc to buy, 9 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
| Analyst Estimates: Analysts believe that the Alnylam Pharmaceuticals, Inc stock has an average upside potential 2027 of 53.21% . Most analysts recommend the Alnylam Pharmaceuticals, Inc stock at Purchase. |
Sales and Margin forecast 2026, 2027 to 2033
33 Analysts have issued a sales forecast Alnylam Pharmaceuticals, Inc 2026 . The average Alnylam Pharmaceuticals, Inc sales estimate is
This results in the following potential growth metrics:
11 Analysts have issued an Alnylam Pharmaceuticals, Inc EBITDA forecast 2026. The average Alnylam Pharmaceuticals, Inc EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
32 Alnylam Pharmaceuticals, Inc Analysts have issued a net profit forecast 2026. The average Alnylam Pharmaceuticals, Inc net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033
32 Analysts have issued a Alnylam Pharmaceuticals, Inc forecast for earnings per share. The average Alnylam Pharmaceuticals, Inc EPS is
This results in the following potential growth metrics and future valuations:
Alnylam Pharmaceuticals, Inc...
Current Alnylam Pharmaceuticals, Inc Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| RBC Capital |
Outperform
➜
Outperform
|
Unchanged | Oct 08 2026 |
| JP Morgan |
Overweight
➜
Overweight
|
Unchanged | Sep 30 2026 |
| HC Wainwright & Co. |
Buy
➜
Buy
|
Unchanged | Sep 21 2026 |
| Jefferies |
Hold
➜
Hold
|
Unchanged | Sep 08 2026 |
| HC Wainwright & Co. |
Buy
➜
Buy
|
Unchanged | Sep 02 2026 |
| BMO Capital |
Outperform
➜
Outperform
|
Initiated | Aug 19 2026 |
| Wells Fargo |
Equal-Weight
➜
Equal-Weight
|
Unchanged | Aug 14 2026 |
| Analyst Rating | Date |
|---|---|
|
Unchanged
RBC Capital:
Outperform
➜
Outperform
|
Oct 08 2026 |
|
Unchanged
JP Morgan:
Overweight
➜
Overweight
|
Sep 30 2026 |
|
Unchanged
HC Wainwright & Co.:
Buy
➜
Buy
|
Sep 21 2026 |
|
Unchanged
Jefferies:
Hold
➜
Hold
|
Sep 08 2026 |
|
Unchanged
HC Wainwright & Co.:
Buy
➜
Buy
|
Sep 02 2026 |
|
Initiated
BMO Capital:
Outperform
➜
Outperform
|
Aug 19 2026 |
|
Unchanged
Wells Fargo:
Equal-Weight
➜
Equal-Weight
|
Aug 14 2026 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
